[go: up one dir, main page]

EP4251162A1 - Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine - Google Patents

Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine

Info

Publication number
EP4251162A1
EP4251162A1 EP20963799.0A EP20963799A EP4251162A1 EP 4251162 A1 EP4251162 A1 EP 4251162A1 EP 20963799 A EP20963799 A EP 20963799A EP 4251162 A1 EP4251162 A1 EP 4251162A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
immediate release
release pharmaceutical
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20963799.0A
Other languages
German (de)
English (en)
Other versions
EP4251162A4 (fr
Inventor
Erol KIRESEPI
Ersin Yildirim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santa Farma Ilac Sanayi AS
Original Assignee
Santa Farma Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi AS
Publication of EP4251162A1 publication Critical patent/EP4251162A1/fr
Publication of EP4251162A4 publication Critical patent/EP4251162A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to an immediate release pharmaceutical formulation comprising Vortioxetine HBr butanol solvate and at least one pharmaceutically acceptable excipient manufactured by using direct compression method.
  • Vortioxetine the chemical name of which is 1-[2-(2, 4-dimethyl-phenylsulfanyl)-phenyl]- piperazine, is an antagonist on the 5-HT3, 5-HT7 and 5-HT1D receptors, an agonist on the 5- HT1A receptor and a partial agonist on the 5-HT1B receptor and an inhibitor of the serotonin transporter.
  • Vortioxetine is reported to raise the levels of the neurotransmitters serotonin, noradrenalin, dopamine, acetylcholine and histamine in specific areas of the brain
  • Vortioxetine is declared to be a safe and efficacious treatment for depression.
  • MDD major depressive disorder
  • Vortioxetine is C 18 H 22 N 2 S.HBr and its relative molecular mass is 298.45 mg/mol as a free base and 379.36 mg/mol as the hydrobromide salt.
  • the chemical structure of Vortioxetine is shown in the Formula I.
  • Vortioxetine hydrobromide appears as a white to very slightly beige powder, non-hygroscopic, soluble in methanol and ethanol and slightly soluble in water and aqueous solutions at pH 2.0 to 8.3. Its pKa is 9.1 as the free base and 3.0 as the salt.
  • Vortioxetine base and its pharmaceutically acceptable acid addition salts first have been described in EP1436271 by H. Lundbeck A/S. Vortioxetine hydrobromide presents polymorphism and exhibits in four polymorphs, and also it has a non-chiral molecular structure.
  • Vortioxetine HBr was firstly commercially authorized in FDA by the U.S. Food &Drug Administration in September 2013. The medicinal product of it available on the market at film- coated tablet comprising Vortioxetine as the HBr salt and as an oral drop solution comprising Vortioxetine as the DL lactate salt under the name of the BRINTELLIX® which are used for the treatment of major depressive disorder (MDD) in adults.
  • MDD major depressive disorder
  • BRINTELLIX® film-coated tablet is presented as immediate-release dosage form in strengths of 5, 10, 15 or 20 mg of Vortioxetine as the active substance wherein each tablet contains 6.355 mg, 12.71 mg, 19.065 mg, or 25.42 mg of Vortioxetine HBr equivalent to 5 mg, 10 mg, 15 mg, or 20 mg of Vortioxetine, respectively.
  • Other ingredients in the film-coated tablets are mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate and magnesium stearate which are present in the tablet core and hypromellose, macrogol 400, titanium dioxide and iron oxide red and/or iron oxide yellow present in the tablet coating.
  • the recommended starting dose is 10 mg administered orally once daily without regard to meals and the dose should then be increased to 20 mg/day, as tolerated.
  • Vortioxetine is slowly absorbed after oral administration of immediate release tablets or solution. Following single and multiple oral doses of 5, 10, or 20 mg for immediate release, median t max values of 7 to 11 hours were observed. The reported absolute bioavailability (BA) was approximately 75%. The administration of 20 mg Vortioxetine did not have a statistically significant effect on gastric emptying, but did have a statistically significant pro-kinetic effect on small intestinal transit and subsequent colon arrival.
  • EP2470166 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Vortioxetine or pharmaceutically acceptable acid addition salt thereof, wherein said composition is adapted so that said compound is not released in the stomach.
  • EP2044043 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Vortioxetine or pharmaceutically acceptable acid addition salt thereof wherein the beta form of crystal Vortioxetine hydrobromide salt having XRPD reflections at approximately 6.89, 9.73, 13.78 and 14.64 (2 ⁇ ), and wherein a process for the manufacturing of crystalline hydrobromic acid addition salt is disclosed.
  • EP2421534 relates to a liquid pharmaceutical composition
  • a liquid pharmaceutical composition comprising Vortioxetine or pharmaceutically acceptable acid addition salt thereof wherein the salt is selected from the DL- lactic acid addition salt, L-lactic acid addition salt and the D-lactic acid addition salt.
  • EP2142193 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Vortioxetine or pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutical excipient manufactured by using wet granulation method wherein the composition is used for the treatment of pain.
  • EP3294719 relates to a pharmaceutical composition comprising Vortioxetine pyroglutamate and its use in pharmaceutical compositions manufactured by using direct compression method.
  • EP3184104 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers wherein the at least one polyethylene oxide is present in the matrix in an amount of 75-98 % (w/w) based on the total weight of the matrix, and wherein the composition is prepared by using direct compression method.
  • WO2018065348 relates to an enteric-coated tablet comprising Vortioxetine having a particle size distribution of D90 of 100 ⁇ m or less and at least one pharmaceutically acceptable excipient wherein the tablet core being coated with a pH sensitive coating.
  • WO2017041680 relates to a pharmaceutical composition of an amorphous Vortioxetine or a salt thereof and two or more pharmaceutically acceptable excipients.
  • EP3184102 relates to a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising an inert core comprising, preferably consisting of, at least one acidic reacting compound, and a coating comprising Vortioxetine hydrobromide and at least one pharmaceutically acceptable polymer.
  • WO2018042168 relates to novel premixes of Vortioxetine and at least one pharmaceutically acceptable polymer.
  • WO2017125504 relates to the preparation of novel polymorphic forms of Vortioxetine hydrobromide wherein the preparation of Vortioxetine hydrobromide 2-butanol solvate Form R3 and Form R4 are disclosed.
  • EP3582759 relates to a pharmaceutical composition comprising Vortioxetine hydrobromide having particle size distribution corresponding to D98 100-200 ⁇ , D50 35-90 ⁇ and D5 7-30 ⁇ wherein the composition is manufactured by using wet granulation method.
  • compositions comprising Vortioxetine HBr 2- butanol solvate form H as active ingredient and at least one pharmaceutically acceptable excipient manufactured by using direct compression method can overcome all the problems stated above and pharmaceutical compositions with improved solubility and hygroscopicity can be obtained.
  • the object of this invention is to develop an immediate release solid oral pharmaceutical composition
  • a therapeutically effective amount of Vortioxetine HBr 2-butanol solvate which is an antagonist on the 5-HT3, 5-HT7 and 5-HT1D receptors, an agonist on the 5-HT1 A receptor and a partial agonist on the 5-HT1B receptor and an inhibitor of the serotonin transporter.
  • Another object of the present invention is related to an immediate release dosage form composition for the treatment of major depressive disorder (MDD).
  • MDD major depressive disorder
  • Another object of the present invention is to provide an immediate release pharmaceutical formulation comprising Vortioxetine hydrobromide is in crystalline form.
  • the crystalline form exists in the 2-butanol solvate form H.
  • Another object of the present invention is to provide a preparation method of a pharmaceutical composition of Vortioxetine hydrobromide 2-butanol solvate form H wherein the pharmaceutical compositions herein disclosed can be manufactured into solid dosage forms, such as tablets having desired dissolution profiles.
  • Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Vortioxetine hydrobromide 2-butanol solvate and at least one pharmaceutically acceptable excipients manufactured by using direct compression method.
  • Another object of the present invention is to provide a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising Vortioxetine hydrobromide 2-butanol solvate form H manufactured by using direct compression method wherein provided for the manufacture of tablets containing the active ingredient, diluent, disintegrant, binder and lubricant selected as to be the most suitable ones with respect to the intended form of administration.
  • present invention particularly related to provide an immediate release pharmaceutical formulation manufactured by using direct compression method, including the steps of:
  • Vortioxetine hydrobromide 2-butanol solvate Form H Mannitol, Microcrystalline cellulose, Hydroxypropyl methylcellulose and Sodium starch glycolate are screened through a proper sieve and stirred,
  • the present invention provides an immediate release pharmaceutical formulation comprising Vortioxetine hydrobromide 2-butanol solvate form H and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form wherein the prepared composition is manufactured by using direct compression method to get desired dissolution properties.
  • Vortioxetine hydrobromide 2-butanol solvate form H is crystalline and presents characteristic peaks at particularly 6.7°, 13,3°, 16.0° and 19.2° 2-theta angles.
  • Solvates are known to exhibit faster dissolution rate, higher solubility and better bioavailability than the crystal form of active ingredient. However, it is also known that solvate forms are very hygroscopic which may have an impact on processibility of active substance.
  • One of the technical properties of processibility is powder characteristics, because the powder characteristics of active substance are considered while deciding how to handle it during manufacturing process and selecting the excipients used for the formulation design. Thus, flowability is controlled by performing dedicated analysis stated international guidelines.
  • the compressibility index and Hausner ratio were calculated as 35 and 1.54, respectively based on the results of densities 0.426 g/ml (tapped) and 0.277 g/ml (bulk).
  • Table 1 given below shows scale of flowability depending on the value of the Compressibility index and Hausner ratio.
  • Vortioxetine hydrobromide used in reference drug product and Vortioxetine hydrobromide 2-butanol solvate Form H is very different.
  • Vortioxetine hydrobromide presents mean crystal particles, however Vortioxetine hydrobromide 2-butanol solvate form H exhibits damp, fine and bright particles. The damp, fine particles have a tendency to exhibit poor flowability due to the cohesion force arising around the particles.
  • compositions comprising 2-butanol solvate form H of Vortioxetine hydrobromide and at least one pharmaceutically acceptable excipient wherein the composition is manufactured by using the proper manufacturing method. It is known that there is common three manufacturing method like direct compression, dry granulation or wet-granulation. The choice of the proper manufacture process highly depends on the properties of the active ingredient and the excipients preferred.
  • Direct compression refers to the powdered materials are compressed directly without changing the physical and chemical properties of the drug, thus; it is a relatively quick process having less processing steps than other granulation techniques.
  • the manufacturer can blend the active ingredient(s) with other pharmaceutical excipients in a blender or similar apparatus before being compressed into tablets.
  • direct compression makes it difficult to obtain a homogenously acceptable solid dosage form due to the potency of segregation.
  • Vortioxetine hydrobromide 2-butanol solvate form H to be able to exhibit unstable polymorphic characteristics while using wet granulation due to the wetting and drying processes and polymorphic change while using dry granulation due to double tablet compression process.
  • the physicochemical properties of pharmaceutical composition comprising Vortioxetine hydrobromide 2-butanol solvate form H predominantly are affected by the mixing, formulation ingredients, and selection of the proper manufacturing step.
  • the manufacturing step is selected as direct compression method and based on that also convenient pharmaceutically acceptable excipients are preferred.
  • the pharmaceutical composition comprising at least two diluents which can be selected from dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
  • diluents are mannitol and microcrystalline cellulose.
  • the pharmaceutical composition comprises at least a binder which can be selected from hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof.
  • the binder is hydroxypropyl methylcellulose.
  • the pharmaceutical composition comprising at least one disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, corn starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
  • the disintegrant is sodium starch glycolate.
  • the pharmaceutical composition comprising at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
  • the lubricant is magnesium stearate.
  • an immediate release composition comprising Vortioxetine Hydrobromide 2-butanol solvate form H and pharmaceutically acceptable excipients manufactured by using direct compression method can exhibit proper dissolution profiles both in low pH and high pH aqueous solutions as simulation of gastrointestinal fluids.
  • the embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using direct compression method.
  • Example 1 was based on the invention provides an immediate release oral solid pharmaceutical composition wherein the amounts in w/w% by weight of the total composition are as stated below:
  • Table 2 Unit Formula of Example 1 The detailed manufacturing steps are presented below: a. Vortioxetine hydrobromide 2-butanol solvate Form H, Mannitol, Microcrystalline cellulose, Hydroxypropyl methylcellulose and Sodium starch glycolate were screened through a proper sieve and stirred, b. Magnesium stearate was screened through a proper sieve and added to the powder blend prepared in Step a and were stirred to obtain a uniform final blend, c. Tablet compression was performed with the final blend in Step b.
  • flowability of the final blend is controlled by measuring bulk and tapped densities in accordance with USP ⁇ 1174>.
  • the compressibility index and Hausner ratio were calculated as 21 and 1.27, respectively based on the results of bulk and tapped densities which were 0.439 g/ml and 0.556 g/ml. Based on the results of scale of flowability, the final blend had “passable” flow characteristic.
  • volume of dissolution media 900 ml
  • the similarity factor f 2 is the most common comparison index that is used to indicate the similarity of dissolution profiles between examples and reference drug product.
  • the similarity index f 2 parameter should be higher than 50 to be similar with reference drug product.
  • similarity of two drug products can be compared based on the results of in vitro dissolution profile studies of these drug products by using a similarity factor f 2 .
  • the similarity factor f 2 is the most common comparison index and if the estimated value is in the range from 50 to 100, the dissolution profiles of two drug products in comparison are concluded as similar.
  • the similarity factor f 2 of Example 1 was calculated as 55.8 for 0.1N HCI and f 2 was calculated as 50.2 for 6.8 phosphate buffer, which means the developed formulation was suitable.
  • the developed pharmaceutical composition comprising Vortioxetine hydrobromide 2-butanol solvate Form H and at least one pharmaceutically acceptable excipient exhibits similar dissolution profiles both in 0.1N HC1 and pH 6.8 phosphate buffer with the reference drug product, wherein the prepared composition is manufactured by using direct compression method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique à libération immédiate comprenant un solvate de butanol de HBr de vortioxétine et au moins un excipient pharmaceutiquement acceptable fabriqué en faisant appel à un procédé de compression directe.
EP20963799.0A 2020-11-27 2020-11-27 Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine Pending EP4251162A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2020/051190 WO2022115057A1 (fr) 2020-11-27 2020-11-27 Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine

Publications (2)

Publication Number Publication Date
EP4251162A1 true EP4251162A1 (fr) 2023-10-04
EP4251162A4 EP4251162A4 (fr) 2024-08-14

Family

ID=81754740

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20963799.0A Pending EP4251162A4 (fr) 2020-11-27 2020-11-27 Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine

Country Status (2)

Country Link
EP (1) EP4251162A4 (fr)
WO (1) WO2022115057A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
EP3209297A1 (fr) * 2014-10-24 2017-08-30 Hexal Aktiengesellschaft Bromhydrate de vortioxétine amorphe
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
WO2017041680A1 (fr) * 2015-09-07 2017-03-16 常州方楠医药技术有限公司 Composition pharmaceutique à base de vortioxétine ou d'un sel de celle-ci, et son procédé de préparation
CN105193763B (zh) * 2015-09-18 2018-04-20 康普药业股份有限公司 一种氢溴酸沃替西汀片及其制备方法
CN107789327B (zh) * 2016-09-07 2020-06-02 成都康弘药业集团股份有限公司 一种含有氢溴酸沃赛汀的药物组合物及其制备方法
US20180273499A1 (en) * 2017-03-17 2018-09-27 Teva Pharmaceuticals International Gmbh Salts and solid state forms of vortioxetine

Also Published As

Publication number Publication date
EP4251162A4 (fr) 2024-08-14
WO2022115057A1 (fr) 2022-06-02

Similar Documents

Publication Publication Date Title
US11883403B2 (en) Pharmaceutical compositions comprising Afatinib
KR20160101720A (ko) Azd9291을 포함하는 제약 조성물
CA2720851A1 (fr) Compositions pharmaceutiques orales dans une dispersion solide moleculaire
EP2051694A2 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
KR20090016611A (ko) 메만틴의 약학 조성물
AU2019321583C1 (en) Formulations of AG10
JP2015500853A (ja) 即時放出マルチユニットペレットシステム
CN110603035A (zh) 具有改善的水溶解度及生物利用率的组合物
US10588892B2 (en) Pharmaceutical composition comprising sacubitril and valsartan
TW201431569A (zh) 具有高含量菲索芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）之固態單位及其製備方法
US12290601B2 (en) Pharmaceutical composition comprising axitinib
WO2013008253A2 (fr) Formulations d'imatinib
WO2022115057A1 (fr) Procédé de fabrication amélioré pour les formulations comprenant une forme h de solvate de butanol de hbr de vortioxétine
WO2014115082A1 (fr) Formulations pharmaceutiques d'imatinib
CN102349889A (zh) 一种含有决奈达隆的组合物
JP5063368B2 (ja) テリスロマイシンを含む固形医薬組成物
JP6669937B2 (ja) ５−ｈｔ６拮抗薬の医薬組成物
EP4282415A1 (fr) Composition de comprimé stable d'axitinib
WO2022197267A1 (fr) Composition pharmaceutique comprenant du bromhydrate de vortioxétine sous forme cristalline sf
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
JP2011527314A (ja) エプロサルタン組成物
WO2024261701A1 (fr) Formulation d'edoxaban.
JP2019073445A (ja) アプレピタントを有効成分とする医薬組成物
WO2023080854A1 (fr) Compositions de chlorhydrate de lurasidone
JP2019073488A (ja) アプレピタントを有効成分とする医薬錠剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240712

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20240708BHEP

Ipc: A61P 25/24 20060101ALI20240708BHEP

Ipc: A61K 9/28 20060101ALI20240708BHEP

Ipc: A61K 31/495 20060101AFI20240708BHEP